Literature DB >> 25147118

Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease.

Stephen W Scheff1, Douglas A Price1, Mubeen A Ansari1, Kelly N Roberts1, Frederick A Schmitt1, Milos D Ikonomovic2, Elliott J Mufson3.   

Abstract

Mild cognitive impairment (MCI) is considered to be an early stage in the progression of Alzheimer's disease (AD) providing an opportunity to investigate brain pathogenesis prior to the onset of dementia. Neuroimaging studies have identified the posterior cingulate gyrus (PostC) as a cortical region affected early in the onset of AD. This association cortex is involved in a variety of different cognitive tasks and is intimately connected with the hippocampal/entorhinal cortex region, a component of the medial temporal memory circuit that displays early AD pathology. We quantified the total number of synapses in lamina 3 of the PostC using unbiased stereology coupled with electron microscopy from short postmortem autopsy tissue harvested from cases at different stage of AD progression. Individuals in the early stages of AD showed a significant decline in synaptic numbers compared to individuals with no cognitive impairment (NCI). Subjects with MCI exhibited synaptic numbers that were between the AD and NCI cohorts. Adjacent tissue was evaluated for changes in both pre and postsynaptic proteins levels. Individuals with MCI demonstrated a significant loss in presynaptic markers synapsin-1 and synaptophysin and postsynaptic markers PSD-95 and SAP-97. Levels of [3H]PiB binding was significantly increased in MCI and AD and correlated strongly with levels of synaptic proteins. All synaptic markers showed a significant association with Mini-Mental Status Examination scores. These results support the idea that the PostC synaptic function is affected during the prodromal stage of the disease and may underlie some of the early clinical sequelae associated with AD.

Entities:  

Keywords:  Alzheimer's disease; dementia; memory; mild cognitive impairment; synapses

Mesh:

Substances:

Year:  2015        PMID: 25147118      PMCID: PMC4313125          DOI: 10.3233/JAD-141518

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  128 in total

Review 1.  Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology.

Authors:  J J M Hoozemans; R Veerhuis; J M Rozemuller; P Eikelenboom
Journal:  Int J Dev Neurosci       Date:  2005-12-27       Impact factor: 2.457

2.  Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Alzheimers Dis       Date:  2006-07       Impact factor: 4.472

3.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

4.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

5.  Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease.

Authors:  Manja Lehmann; Jonathan D Rohrer; Matthew J Clarkson; Gerard R Ridgway; Rachael I Scahill; Marc Modat; Jason D Warren; Sebastien Ourselin; Josephine Barnes; Martin N Rossor; Nick C Fox
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology.

Authors:  Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Synapse stability in the precuneus early in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Kelly N Roberts; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Authors:  Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

10.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

View more
  59 in total

Review 1.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  J Neural Transm (Vienna)       Date:  2015-05-06       Impact factor: 3.575

2.  In vivo imaging of synaptic loss in Alzheimer's disease with [18F]UCB-H positron emission tomography.

Authors:  Christine Bastin; Mohamed Ali Bahri; François Meyer; Marine Manard; Emma Delhaye; Alain Plenevaux; Guillaume Becker; Alain Seret; Christine Mella; Fabrice Giacomelli; Christian Degueldre; Evelyne Balteau; André Luxen; Eric Salmon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-29       Impact factor: 9.236

3.  Effects of HLA-DRB1/DQB1 Genetic Variants on Neuroimaging in Healthy, Mild Cognitive Impairment, and Alzheimer's Disease Cohorts.

Authors:  Zi-Xuan Wang; Hui-Fu Wang; Lin Tan; Jinyuan Liu; Yu Wan; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-04-07       Impact factor: 5.590

Review 4.  Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders.

Authors:  Milos D Ikonomovic; Zhiping Mi; Eric E Abrahamson
Journal:  Ageing Res Rev       Date:  2016-11-06       Impact factor: 10.895

5.  Inhibition of PTEN Attenuates Endoplasmic Reticulum Stress and Apoptosis via Activation of PI3K/AKT Pathway in Alzheimer's Disease.

Authors:  Weigang Cui; Songtao Wang; Zhongping Wang; Zhiyong Wang; Chunli Sun; Yinghua Zhang
Journal:  Neurochem Res       Date:  2017-08-18       Impact factor: 3.996

6.  Effective expression of Drebrin in hippocampus improves cognitive function and alleviates lesions of Alzheimer's disease in APP (swe)/PS1 (ΔE9) mice.

Authors:  Yan Liu; Yan-Feng Xu; Ling Zhang; Lan Huang; Pin Yu; Hua Zhu; Wei Deng; Chuan Qin
Journal:  CNS Neurosci Ther       Date:  2017-06-08       Impact factor: 5.243

Review 7.  The Role of Synapsins in Neurological Disorders.

Authors:  Fatima Javed Mirza; Saadia Zahid
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

8.  Reproducibility of brain MRS in older healthy adults at 7T.

Authors:  S Andrea Wijtenburg; Laura M Rowland; Georg Oeltzschner; Peter B Barker; Clifford I Workman; Gwenn S Smith
Journal:  NMR Biomed       Date:  2018-11-29       Impact factor: 4.044

Review 9.  Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies.

Authors:  Olga Zolochevska; Giulio Taglialatela
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.

Authors:  Maartje I Kester; Charlotte E Teunissen; Daniel L Crimmins; Elizabeth M Herries; Jack H Ladenson; Philip Scheltens; Wiesje M van der Flier; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-11       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.